| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | NSC23766 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.051 | 0.3 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.4 |